‘In the References section of this Article, the citation listed as reference 17 is incorrect, and should have referred to the following paper:
Forbes, S. A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43(Database issue): D805-D811 (2015).’
Additional information
The online version of the original article can be found at 10.1038/ncomms14013
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Kang, YJ., Balter, B., Csizmadia, E. et al. Correction: Corrigendum: Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival. Nat Commun 8, 15795 (2017). https://doi.org/10.1038/ncomms15795
Published:
DOI: https://doi.org/10.1038/ncomms15795
This article is cited by
-
Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma
Nature Communications (2021)
-
Role of protein kinase CK2 in antitumor drug resistance
Journal of Experimental & Clinical Cancer Research (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
